I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Dengue is an acute infectious disease caused by mosquito and associated with significant mortality and morbidity.\[[@ref1]\] Today about 50% of the world\'s population, live in areas which are endemic for dengue transmission, and around 125 countries are endemic for the same.\[[@ref2]\] Globally, around 50--200 million dengue infection, 500,000 episodes of severe dengue, and 20,000 dengue-related deaths are reported annually.\[[@ref3]\] The incidence and prevalence of dengue infection are expected to increase in future because of changes in climate, travel, socioeconomic status, trade, and viral characteristics.\[[@ref3]\] There is 40% risk of contracting dengue if one resides in the endemic area and out of these, only 0.5% has risk of developing a serious form of the disease. Clinically, dengue causes moderately high-grade fever, rash with severe aches, mostly severe backache, and pain behind the eyes. Following this, there is an apparent phase of improvement and in severe forms symptoms such as vomiting, pain in the abdomen, red spots, reduction in urine output, change in alertness, and bleeding can occur. The red flag sign, citing the severity in serious dengue is a fluid leak from blood vessels and capillaries from the nose, gums, skin, lung vessels, intra-abdominal areas, etc.\[[@ref4]\]

Bleeding of variable severity is seen mainly in the severe form of dengue, i.e., dengue hemorrhagic fever. Pathogenesis of bleeding involves leakage of plasma from the blood vessels. It seems to be due to the destruction of platelets through complement system or depression of bone marrow due to dengue viral infection or both. It is also observed that platelets that escape from the destruction become nonfunctional or less functional.\[[@ref5][@ref6][@ref7]\] Direct correlation between platelet count and prognosis of dengue is reported in many published studies.\[[@ref5][@ref6][@ref8][@ref9][@ref10]\]

With the recent outbreak of dengue in India, there has reportedly been a sudden increase in the demand for papaya leaves juice across India. The print media, social network, and national media have started coming up with opinion pieces, news items, and blogs on the use of papaya in the treatment of dengue which was instantly taken up by the community due to its perceived beneficial effect on the platelet count.\[[@ref11]\] Literature cites the therapeutic effects of aqueous extract of papaya (*Carica papaya*) leaves that are presumed to be due to several active components (flavonoids, alkaloids, enzymes, and minerals) which may have antioxidant and immunomodulatory effects.\[[@ref12][@ref13][@ref14][@ref15]\]

With the outpouring of above information, there was a need of systematic search and analysis of available evidence as a guideline for the use of papaya in the treatment of dengue; hence, this systematic review was planned to explore the efficacy and safety of *C. papaya* in dengue.

M[ATERIALS AND]{.smallcaps} M[ETHODS]{.smallcaps} {#sec1-2}
=================================================

Outcomes {#sec2-1}
--------

The primary outcome was the comparison of mortality between *C. papaya* and control. Secondary outcomes included platelet counts, hospitalization time, and adverse events.

Search methods and identification of studies {#sec2-2}
--------------------------------------------

A systematic search was performed in PubMed, Cochrane Clinical Trial Registry, and Google Scholar \[[Appendix 1](#APP1){ref-type="app"}\]. References of published articles were hand searched to find new studies exploring the efficacy and safety of *C. papaya* in dengue.

Study selection {#sec2-3}
---------------

Randomized controlled trials exploring the role of *C. papaya* compared with any comparator for patients of dengue and dengue shock syndrome were eligible for inclusion. Case reports and observational studies were not included in the analysis. Two review authors (Jaykaran Charan and Deepak Saxena) assessed titles and abstracts followed by full text (using predefined inclusion criteria) independently. For any disagreement decision of third author (Jagdish Prasad Goyal) was considered final.

Data collection and analysis {#sec2-4}
----------------------------

### Data extraction and management {#sec3-1}

Two review authors (Jaykaran Charan and Deepak Saxena) extracted the data from included trials using a standardized data extraction form independently. Data were collected on study characteristics, patient characteristics, treatment characteristics, risk of bias using Cochrane risk of bias tool, and outcome data (mortality, platelet counts, hospitalization time, adverse events, etc.).

Statistical analysis {#sec2-5}
--------------------

Continuous data were summarized as mean difference (MD) and standardized MD (SMD) with 95% confidence interval (CI). The unit of MD was × 10^3^/µl. In case of one clinical trial, the standard deviation of one follow-up parameter (increase in platelet count) was not given. On the basis of standard deviation of other parameter of same study and parameters of other studies, it was observed that there was not much difference in standard deviation between baseline and follow--up; hence, for that study (Yunita *et al*.), we considered follow-up standard deviation (SD) same as baseline SD during analysis results of Yunita *et al*. was given as subgroup to clarify the effect of this study on overall results. Dichotomous data was summarized as risk ratio (RR) with 95% CI. Random effect model was used for the analysis. Heterogeneity was calculated using *I*^2^ values. We set predecided criteria for significant heterogeneity (*I*^2^ \> 50%).

We did not asses the publication bias as there were only four trials fulfilling the inclusion criteria, which were too less for assessing the publication bias. Review Manager version 5.3 software (Cochrane Collaboration) was used for analysis. This review was performed as per the standards of Cochrane Collaboration and reported as per PRISMA standards.\[[@ref16]\]

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Study characteristics {#sec2-6}
---------------------

There were total four trials included in the analysis.\[[@ref13][@ref17][@ref18][@ref19]\] Step by step method of inclusion and exclusion of studies is depicted in [Figure 1](#F1){ref-type="fig"}. All studies were single-center randomized trials, except one which was multicentric. No trial was double-blind. Only one trial was placebo controlled trial, and in rest, standard treatments were considered as control. *C. papaya* was used by the different method in each trial. In one trial, it was used as leaf extract juice, in the second trial, it was used as leaf extract tablet and in remaining two trials, it was used as leaf extract capsule and leaf extract syrup, respectively. Follow-up was not same in all trials. It was 2 days, 5 days, 4 days, and 5 days, respectively \[[Table 1](#T1){ref-type="table"}\].

![PRISMA chart](IJABMR-6-249-g001){#F1}
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Assessment of bias {#sec2-7}
------------------

Many of the parameters needed for the assessment of the risk of bias were not reported in these trials. As none of the trials was double-blinded; hence, there is a chance of bias, but at the same time, endpoints such as platelet counts are objective parameters; hence, incorporation of the bias by open labeling of the trial may not significantly affect the result \[[Figure 2](#F2){ref-type="fig"}\].

![Risk of bias graph](IJABMR-6-249-g003){#F2}

Efficacy of intervention {#sec2-8}
------------------------

### Mortality {#sec3-2}

Data on mortality were not given in any trial; hence, the analysis could not be done for the primary endpoint.

### Change in platelet count for all follow-ups {#sec3-3}

Data were extracted from the four clinical trials (377 subjects) \[[Figure 3](#F3){ref-type="fig"}\].\[[@ref13][@ref17][@ref18][@ref19]\] *C. papaya* compared with control was associated with a statistically significant increase in platelet count (MD = 20.27 \[95% CI 6.21--34.73; *P* = 0.005\]). There was significant heterogeneity (*I*^2^ = 50%). Similar results were obtained after excluding Yunita *et al*. \[[Figure 3](#F3){ref-type="fig"}\]. Same results were obtained for the (SMD = 0.46 \[95% CI 0.13--0.78; *P* = 0.006\], *I*^2^ = 45%).

![Efficacy of *Carica papaya* on platelet count (mean difference) for all follow-ups](IJABMR-6-249-g004){#F3}

In the case of number of subjects whose platelet count reach to normal range, the data were extractable from only one study enrolling total 39 patients.\[[@ref18]\] There was no significant difference between *C. papaya* and control for the subjects whose platelet count reached to the normal level (RR = 0.53, 95% CI 0.22--1.29; *P* = 0.16).

### Change in platelet count after 48 h {#sec3-4}

Data were extracted from the four clinical trials (377 subjects) \[[Figure 4](#F4){ref-type="fig"}\].\[[@ref13][@ref17][@ref18][@ref19]\] There was no significant difference in rise in platelet count between *C. papaya* and control (MD = 13.38 \[95% CI − 7.71--34.51; *P* = 0.21\]). There was significant heterogeneity between subgroups (*I*^2^ = 85%). On excluding Yunita *et al*. from the analysis MD and CI range got decreased, but the difference was still insignificant \[[Figure 4](#F4){ref-type="fig"}\] and heterogeneity disappeared. Same results were obtained for the (SMD = 0.32 \[95% CI − 0.21--0.86; *P* = 0.23\], *I*^2^ = 79%).

![Efficacy of *Carica papaya* on platelet count (mean difference) after 48 h](IJABMR-6-249-g005){#F4}

### Change in platelet count after 4 days {#sec3-5}

Data were extracted from three clinical trials (149 subjects) \[[Figure 5](#F5){ref-type="fig"}\].\[[@ref17][@ref18][@ref19]\] *C. papaya* administration was significantly associated with increase in platelet count as compared to the control (MD = 28.25 \[95% CI 14.14--42.37; *P* \< 0.0001\]). There was no heterogeneity observed (*I*^2^ = 0%), and similar results were obtained for the (SMD = 0.58 \[95% CI 0.25--0.91; *P* \< 0.0006\], *I*^2^ = 31%).

![Efficacy of *Carica papaya* on platelet (mean difference) after 4 days](IJABMR-6-249-g006){#F5}

### Hospitalization days {#sec3-6}

Data for this endpoint was extractable from one study enrolling total eighty subjects.\[[@ref17]\] *C. papaya* was significantly associated with decrease in hospitalization days as compared to control (MD = 1.90 \[95% CI 1.62--2.18; *P* \< 0.00001\]).

Safety of intervention {#sec2-9}
----------------------

### Adverse events {#sec3-7}

There were no specific data given about adverse events in the published studies. In two studies, it was mentioned that there were no significant adverse events observed in both intervention and control groups.\[[@ref13][@ref18]\]

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

On the basis of this review it can be summarized that *C. papaya* is significantly associated with the increase in platelet counts in the patients of dengue. The results are consistent even after excluding (Yunita *et al*. 2012) study in which standard deviation of platelet counts was not given in follow-up. Data related to the mortality and adverse events were not available.

The most important finding of this systematic review is increase in platelet count was significantly more in *C. papaya* group as compared to the control group. Platelet count is not considered among the criteria for severe dengue and considered as warning sign only as per the WHO guidelines; however, studies supported the predictive ability of platelet count for the severity of dengue.\[[@ref8][@ref20]\] Platelet count also correlates with vascular leakage of proteins and liver damage.\[[@ref21]\] The major pathophysiological hallmark which determines dengue severity is vascular leakage.\[[@ref22]\] Therefore, thrombocytopenia might be an important predictor of mortality. There was a modest rise in the platelet count in this review with wider CIs in all analysis which indicates inconsistency in the results. There are very few studies available, regarding actual mechanism of beneficial effect of *C. papaya* leaf extract in dengue. In a "*in vitro*" study by Ranasinghe *et al*., the *C. papaya* leaf extract found to be associated with the improvement of erythrocyte membrane stabilization.\[[@ref23]\] A study done by bioinformatics methods found that flavonoids of *C. papaya* leaf extract can inhibit a protease involved in viral assembly.\[[@ref14]\] The leaf extract of *C. papaya* has antioxidant and free radical scavenging property which can help in the prevention of hemolysis and bleeding.\[[@ref24]\]

This is so far best available evidence for the use of *C. papaya* in dengue patients. Majority of the parameters, through which bias can be evaluated were not reported in these clinical trials. In the absence of these information authenticity of the results obtained in these clinical trials cannot be considered free of bias. However, platelet count is a laboratory parameter and not a subjective criteria; hence, chances of any bias due to open label nature of trials is less. These trials were conducted in Asian countries where the prevalence of dengue fever is high, so the results of these trials cannot be applied to other countries and people with different genetic makeups.

C[ONCLUSION]{.smallcaps} {#sec1-5}
========================

On the basis of this systematic review and meta-analysis, it can be concluded that *C. papaya* leafs extract has a definitive role in improving the platelet count in patients of dengue. Looking at the wider CI, the rise in platelet count may be very less and may not be clinically significant. There is a statistically significant positive effect on the rise of platelet count, but whether this rise is clinically significant or not? That can be explored further by designing high-quality clinical trials based on large sample size with all measures to prevent incorporation of bias.

Implications for practice {#sec2-10}
-------------------------

On the basis of this study, the use of *C. papaya* in dengue cannot be suggested as data of safety was not properly measured and reported in the included clinical trials. The rise in platelet count may also be too less to affect the outcome. More evidence needed in the form of well-designed clinical trials before a decision on the use of *C. papaya* leaf extract are made.

Implications for research {#sec2-11}
-------------------------

There are good indications that intervention may be useful in dengue patients; hence, the role of *C. papaya* leaf extract should be explored further through better designed clinical trials.
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**Steps for Search**

Step-1: Dengue\*

Step-2: "Dengue Fever"

Step-3: "Dengue" AND "treatment"

Step-4: "Dengue" AND "treatment" \[ti/ab\]

Step-5: " Dengue" OR "Dengue fever" AND "treatment" \[ti/ab\] AND/OR "Papaya"

Step-6: " Dengue" OR "Dengue fever" AND "treatment" OR "management" OR "health status" \[ti/ab\] AND/OR "Papaya"

Step-7: " Dengue" OR "Dengue fever" AND "treatment" OR "management" OR "health status" \[ti/ab\] AND/OR "Papaya" AND Randomized Controlled Trial \[ptyp\]
